BIOS Health, a neural engineering company, is set to deploy its Neural Digital Therapy platform in a groundbreaking study funded by the US National Institutes of Health (NIH). The study will take place across eight clinics worldwide, marking a significant advancement in the application of neural interfaces and artificial intelligence in healthcare.
The Neural Digital Therapy platform aims to improve patient outcomes by analyzing neural data in real-time. This technology has the potential to personalize medicines and tailor treatments to individual patient needs. BIOS Health's platform identifies neural biomarkers, linking nerve activity to various health conditions with precision.
"Our mission is to improve patient quality of life through neural engineering," states BIOS Health. The company's technology is designed to address conditions such as hypertension, diabetes, rheumatoid arthritis, and potentially brain diseases like Alzheimer's. By harnessing the vast data within the human nervous system, BIOS Health seeks to create a new generation of personalized medicines.
BIOS Health is expanding its global footprint, establishing a cutting-edge research and clinical trials center in California. This follows the launch of an AI and neuroscience research site in Canada in 2018. These expansions underscore the company's commitment to advancing neural engineering and personalized medicine on a global scale.
The company scaled rapidly after securing a major venture round in 2023, supported by prominent investors and industry leaders. This funding has enabled BIOS Health to further develop its technology and expand its research capabilities. The BIOS neural insights platform can analyze extensive data from the nervous system to link nerve activity to health conditions through the discovery of neural biomarkers.
